tradingkey.logo

Arcturus Therapeutics Holdings Inc

ARCT

19.620USD

+1.570+8.70%
收盘 09/18, 16:00美东报价延迟15分钟
532.64M总市值
亏损市盈率 TTM

Arcturus Therapeutics Holdings Inc

19.620

+1.570+8.70%
关于 Arcturus Therapeutics Holdings Inc 公司
Arcturus Therapeutics Holdings Inc. 是一家全球信使 RNA 药物和疫苗公司。该公司专注于传染病疫苗的开发以及肝脏和呼吸系统罕见疾病领域的重大机遇。除了信使 RNA (mRNA) 平台外,其脂质纳米颗粒 (LNP) 递送系统 LUNAR 还具有实现多种核酸药物的潜力,其自扩增 mRNA 技术(自转录和复制 RNA (STARR) 技术)有可能在较低剂量水平下提供更持久的 RNA 和持续的蛋白质表达。该公司正在利用其 LUNAR 平台和核酸技术开发和推进基于 mRNA 的疫苗和疗法,用于治疗具有重大未满足医疗需求的传染病和罕见遗传疾病。其基于 STARR 技术平台的 COVID-19 候选疫苗正在进行 II 期临床试验。
公司简介
公司代码ARCT
公司名称Arcturus Therapeutics Holdings Inc
上市日期May 22, 2013
CEOMr. Joseph E. Payne
员工数量174
证券类型Ordinary Share
年结日May 22
公司地址10628 Science Center Dr Ste 250
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121-1132
电话18589002660
网址https://arcturusrx.com/
公司代码ARCT
上市日期May 22, 2013
CEOMr. Joseph E. Payne
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Andrew H. (Andy) Sassine
Mr. Andrew H. (Andy) Sassine
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Joseph E. Payne
Mr. Joseph E. Payne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.48M
--
Dr. Padmanabh Chivukula
Dr. Padmanabh Chivukula
Chief Operating Officer, Chief Scientific Officer
Chief Operating Officer, Chief Scientific Officer
435.33K
--
Mr. Lance Kurata
Mr. Lance Kurata
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Dr. Adm. Jing L. Marantz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Edward W. Holmes, M.D.
Dr. Edward W. Holmes, M.D.
Independent Director
Independent Director
--
--
Mr. James F. Barlow
Mr. James F. Barlow
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
17.29%
BlackRock Institutional Trust Company, N.A.
7.90%
Amova Asset Management Co., Ltd.
6.75%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
其他
55.09%
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
17.29%
BlackRock Institutional Trust Company, N.A.
7.90%
Amova Asset Management Co., Ltd.
6.75%
The Vanguard Group, Inc.
6.67%
ARK Investment Management LLC
6.32%
其他
55.09%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
41.79%
Investment Advisor
28.19%
Hedge Fund
12.35%
Individual Investor
7.87%
Research Firm
5.49%
Insurance Company
1.01%
Pension Fund
0.52%
Bank and Trust
0.14%
其他
2.64%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
391
26.78M
98.75%
-3.73M
2025Q1
403
27.75M
102.37%
-3.11M
2024Q4
400
27.43M
101.26%
-2.26M
2024Q3
404
26.95M
99.66%
-3.33M
2024Q2
409
27.79M
102.77%
-2.68M
2024Q1
391
28.99M
107.82%
+144.88K
2023Q4
376
27.09M
101.05%
-1.26M
2023Q3
373
26.77M
100.23%
-170.02K
2023Q2
355
26.49M
99.74%
-2.09M
2023Q1
361
26.10M
98.32%
-2.45M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Federated Hermes Global Investment Management Corp.
4.69M
17.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
7.82%
-29.89K
-1.39%
Mar 31, 2025
Amova Asset Management Co., Ltd.
1.93M
7.1%
-138.97K
-6.73%
Mar 31, 2025
The Vanguard Group, Inc.
1.74M
6.43%
+64.37K
+3.83%
Mar 31, 2025
ARK Investment Management LLC
2.01M
7.41%
+74.63K
+3.86%
Mar 31, 2025
Payne (Joseph E)
1.48M
5.46%
--
--
Apr 08, 2025
State Street Global Advisors (US)
1.28M
4.72%
-45.71K
-3.45%
Mar 31, 2025
Balyasny Asset Management LP
938.19K
3.46%
+389.43K
+70.97%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
825.77K
3.04%
-23.32K
-2.75%
Mar 31, 2025
Woodline Partners LP
780.44K
2.88%
-26.47K
-3.28%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
ARK Genomic Revolution ETF
2.02%
WisdomTree BioRevolution Fund
1.67%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
iShares Genomics Immunology and Healthcare ETF
0.74%
AXS Green Alpha ETF
0.47%
Global X Genomics & Biotechnology ETF
0.36%
ALPS Medical Breakthroughs ETF
0.2%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
查看更多
ARK Genomic Revolution ETF
占比2.02%
WisdomTree BioRevolution Fund
占比1.67%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.14%
iShares Genomics Immunology and Healthcare ETF
占比0.74%
AXS Green Alpha ETF
占比0.47%
Global X Genomics & Biotechnology ETF
占比0.36%
ALPS Medical Breakthroughs ETF
占比0.2%
SPDR S&P Biotech ETF
占比0.12%
iShares Micro-Cap ETF
占比0.07%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.07%
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
KeyAI